FDA grants Fast Track Designation to telitacicept as a treatment for systemic lupus erythematosus

Telitacicept is a novel recombinant TACI-Fc (transmembrane activator and calcium modulator and cyclophilin ligand interactor) fusion protein that inhibits the development and survival of plasma cells and mature B cells, which are implicated in several autoimmune diseases.


Biospace Inc.